Nuvation Bio Reports Third-Quarter 2026 Results, $45 Million Revenue
Nuvation Bio reported $45.0 million in third-quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI.
Story updates
09:15:08 PM UTC
SquawkNews
Nuvation Bio reported third-quarter 2026 revenue of $45 million, up from $13.1 million a year earlier, while its net loss narrowed to $41.9 million from $55.8 million. Diluted loss per share was $(0.12), compared with $(0.16) in the prior-year quarter.Financial HighlightsBusiness HighlightsOriginal…
09:15:19 PM UTC
SquawkNews
Nuvation Bio 3Q 2026: Revenue $45M, Net loss $41.9M, EPS $(0.12) — 10-Q Summary
Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI® (taletrectinib)IBTROZI continues to be the most prescribed ROS1 TKI and established as the ROS1 market leader in new patient starts and total active patients for both first-line a…